Abivax SA ADS/$ABVX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Abivax SA ADS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Ticker
$ABVX
Sector
Primary listing
Employees
67
Headquarters
Website
Abivax SA ADS Metrics
BasicAdvanced
$9.8B
-
-$5.28
-0.25
-
Price and volume
Market cap
$9.8B
Beta
-0.25
52-week high
$148.83
52-week low
$4.77
Average daily volume
2M
Financial strength
Current ratio
7.863
Quick ratio
7.737
Long term debt to equity
8.722
Total debt to equity
14.472
Interest coverage (TTM)
-14.95%
Profitability
EBITDA (TTM)
-257.849
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,526.64%
Operating margin (TTM)
-4,123.61%
Revenue per employee (TTM)
$94,640
Management effectiveness
Valuation
Price to revenue (TTM)
1,277.992
Price to book
16.23
Price to tangible book (TTM)
17.06
Price to free cash flow (TTM)
-39.562
Free cash flow yield (TTM)
-2.53%
Free cash flow per share (TTM)
-3.087
Growth
Revenue change (TTM)
-42.89%
Earnings per share change (TTM)
44.55%
3-year revenue growth (CAGR)
-11.08%
10-year revenue growth (CAGR)
30.76%
3-year earnings per share growth (CAGR)
22.68%
10-year earnings per share growth (CAGR)
12.08%
Abivax SA ADS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abivax SA ADS stock?
Abivax SA ADS (ABVX) has a market cap of $9.8B as of January 26, 2026.
What is the P/E ratio for Abivax SA ADS stock?
The price to earnings (P/E) ratio for Abivax SA ADS (ABVX) stock is 0 as of January 26, 2026.
Does Abivax SA ADS stock pay dividends?
No, Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders as of January 26, 2026.
When is the next Abivax SA ADS dividend payment date?
Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Abivax SA ADS?
Abivax SA ADS (ABVX) has a beta rating of -0.25. This means that it has an inverse relation to market volatility.